Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2b + probiotics
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Subcutaneous, Oral
01
Overview
"peginterferon alfa-2b + probiotics" is an investigational combination therapy primarily studied for the treatment of chronic viral hepatitis, such as Hepatitis C and B. This regimen combines peginterferon alfa-2b, an immunomodulatory protein, with probiotics, which are live beneficial microorganisms. Peginterferon alfa-2b works by simulating the body's natural antiviral response. The rationale for adding probiotics, such as strains of *Lactobacillus* and *Bifidobacterium*, is to modulate the gut microbiome. Research suggests this modulation can positively influence the gut-liver axis, potentially enhancing the host's immune response against the virus and improving the efficacy of the interferon treatment. [18, 25] Studies have shown that this combination can enhance patient responses to therapy, as indicated by a reduction in viral load. [18]
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on peginterferon alfa-2b + probiotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2b + probiotics.